You do not have permission to access this chart.
Please Sign Up or Login

About:

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of various cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of advanced or metastatic breast cancer. The company also develops ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, Inc. was founded in 2014 and is based in New York, New York.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

110

Address:

Zentalis Pharmaceuticals, Inc. 530 Seventh Avenue Suite 2201 New York NY 10018 United States

Website:

http://www.zentalis.com

Phone:

212-433-3791

Leave a comment

Your email address will not be published. Required fields are marked *